Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.54B P/E 30.13 EPS this Y 16.00% Ern Qtrly Grth 88.90%
Income 105.5M Forward P/E 38.48 EPS next Y 26.60% 50D Avg Chg 7.00%
Sales 482.38M PEG -0.55 EPS past 5Y 4.84% 200D Avg Chg 8.00%
Dividend N/A Price/Book 6.08 EPS next 5Y -41.40% 52W High Chg -17.00%
Recommedations 1.80 Quick Ratio 4.07 Shares Outstanding 103.52M 52W Low Chg 40.00%
Insider Own 11.42% ROA 11.13% Shares Float 84.87M Beta 0.47
Inst Own 83.53% ROE 21.05% Shares Shorted/Prior 20.22M/19.64M Price 25.01
Gross Margin 98.66% Profit Margin 22.00% Avg. Volume 544,877 Target Price 42.80
Oper. Margin 23.39% Earnings Date May 1 Volume 558,972 Change 0.04%
About Corcept Therapeutics Incorporat

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporat News
03/27/24 Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
03/25/24 Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
03/22/24 Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?
02/17/24 Corcept Therapeutics Full Year 2023 Earnings: Beats Expectations
02/16/24 Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
02/16/24 Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript
02/16/24 Q4 2023 Corcept Therapeutics Inc Earnings Call
02/15/24 Corcept Therapeutics Inc Reports Significant Revenue Growth and Net Income Increase in Q4 and ...
02/15/24 Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
02/15/24 Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
02/14/24 Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
02/14/24 Jim Simons Bolsters Position in Corcept Therapeutics Inc
02/08/24 Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
01/29/24 Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
01/29/24 Corcept Appoints Roberto Vieira as President, Oncology
01/09/24 Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
01/08/24 Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
01/04/24 Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
01/02/24 Corcept Therapeutics Stock Is Down 27%. It’s an ‘Ideal Buying Opportunity.’
01/02/24 Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
CORT Chatroom

User Image gucag006 Posted - 17 hours ago

$CORT As of 3/15/24, the short interests in CORT remained stubbornly high at 20.2M out of the float of 103M, i.e., 20% of shares were shorted. Consider the tute's ownership stands at 83.5% and insiders another 11.4%. it is obvious that most of the shorts were professional shorties behind sophisticated computers connected by state-of-the-art fiber network. The fact that the SP around mid $20's and PE at 26 shows that the shorties are not in control here, and the credits go to the management of CORT. Not only the shorties failed to control with overwhelming force, the company is self-funding a long list of clinical trials for major diseases. Folks, we will see SP>$60 next year and triple digits SP in 2 to 3 years. When the Relacorilant hit the market early next year, we will start to see the retreat of Shorties in droves.

User Image BullYa Posted - 1 day ago

$CORT Insider Sells $430,475.00 in Stock

User Image JR603 Posted - 2 days ago

$CORT So what kind of payout should investors hope for from the class action suit? I see $14M is the settlement but I assume the lawyers will get their claws into those $$ before the investors get any bite of the apple that's remaining.

User Image Psalms23 Posted - 3 days ago

@insiderbuyingselling $CORT is trending upward slow and steady. Three key factors: 1. Planned buyback; 2. very low debt and 3. diversified product portfolio. The stock presents low downside risk with high upside potential. Vanguard also stepped in with a new investment position. Short position is approx. 22% which makes no sense and indicates stock manipulation. When this unwinds the stock price will reflect its true value.

User Image BullYa Posted - 1 week ago

$CORT looking forward 25-26 📈 tmrw

User Image Psalms23 Posted - 1 week ago

$CORT Volume was significant around 11 am. This is a major move upward on a stock with 21% short interest.

User Image UncleStock Posted - 1 week ago

$CORT $UTHR $EXEL $VRTX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image BullYa Posted - 1 week ago

$CORT last call

User Image BullYa Posted - 1 week ago

$CORT now let's go

User Image BullYa Posted - 1 week ago

$CORT looks like it's an opportunityto load it up right here for starters

User Image ca_rott1487 Posted - 2 weeks ago

$CORT You can still file for this claim.

User Image BullYa Posted - 3 weeks ago

$CORT $20 should be the bottom in next few days 📉

User Image insiderbuyingselling Posted - 3 weeks ago

$CORT new insider selling: 2200 shares. http://insiderbuyingselling.com/?t=CORT

User Image gucag006 Posted - 3 weeks ago

$CORT Near term upsides were capped not by the law suite, but by the revenue potential of Korlym. I think the fair market value with Korlym is about $30. The upward movement of the SP can only come from the commercialization of Relacorilant and other cancer drugs. The timing for the appeal court judgement on the patent case should come after the approval of Relacorilant, which should replace Korlyme for the entire Cushing Syndrome population, while Korlym can only serve less than half of this group due to the undesirable side effects of Korlym. The patent case has much less impact on CORT's SP, but the P3 trial of Relacorilant and its subsequent approval and commercialization are much more important to the uplifting of its SP.

User Image gucag006 Posted - 3 weeks ago

$CORT This was an ancient case settled long time ago, and has absolutely no material consequence on CORT's P&L and balance sheet as well as its current and future operations. Folks, please be aware of this is part of a concerted attempt to bring the SP down by the shorties. So, you're informed.

User Image DailyStocksPicks Posted - 3 weeks ago

$PRGO might be considered oversold following its latest earnings announcement. Despite surpassing earnings expectations, the company reported sales figures that didn't meet projections. This, coupled with a 2024 outlook that didn’t align with analyst expectations, could have contributed to negative market sentiment. However, it's crucial to recognize that Perrigo also reported record net sales for the fourth quarter and the full year of 2023, demonstrating solid operational performance. Moreover, the launch of an efficiency program suggests strategic steps are being taken to enhance future growth. These factors, when juxtaposed with the stock’s market reaction, suggest that Perrigo’s current stock valuation might not fully reflect the company’s underlying financial health and future potential. $CORT, $SUPN, $PCRX, $JAZZ For more details https://youtu.be/VTKGlSe8Cn4

User Image ca_rott1487 Posted - 3 weeks ago

$CORT Settles for $14M with investors to end claims over misinformation. you can file for compensation if you were affected by this, here. CasePage:https://11thestate.com/cases/corcept-securities-settlement

User Image gucag006 Posted - 3 weeks ago

$CORT It's hilarious to watch there two guys battling to put long and short SP on the pre-hour ticker tape. You know this time and age, there is no material consequence of these type of activities, other than wasting their time and lunch money. https://www.nasdaq.com/market-activity/stocks/cort/pre-market-trades

User Image DailyStocksPicks Posted - 3 weeks ago

$PRGO Perrigo Company plc's stock might be considered oversold following its latest earnings announcement. Despite surpassing earnings expectations, the company reported sales figures that didn't meet projections. This, coupled with a 2024 outlook that didn’t align with analyst expectations, could have contributed to negative market sentiment. However, it's crucial to recognize that Perrigo also reported record net sales for the fourth quarter and the full year of 2023, demonstrating solid operational performance. Moreover, the launch of an efficiency program suggests strategic steps are being taken to enhance future growth. These factors, when juxtaposed with the stock’s market reaction, suggest that Perrigo’s current stock valuation might not fully reflect the company’s underlying financial health and future potential. $CORT $SUPN $PCRX $JAZZ For more details https://youtu.be/5WSzPuYhAF0

User Image gucag006 Posted - 02/29/24

$CORT is a small pharma. If you didn't know the company and I told you the long list of self-funded clinical trial the company is currently running, you probably will think this is BP with MC in the hundred billions. Here is the list: 1) Relacorilant P3 trial Single receptor cortisol blocker, potentially may double or triple its revenue as the currently approved drug Korlym is a multiple receptor cortisol blocker, which cannot be used more than half of the Cushing Syndrome patients due to undesirable side effects. 2) Ovarian cancel P3 trial, 3) ALS (Lou Gehrig's disease) P2 trial, 4) NASH (fatty liver) P1 trial, 5) Breast cancer P2 trial, 6) Prostate cancer P2 trial, 7) Alzheimer’s disease P2 trial, 8) PTSD P2 trial, 9) Major depression P2 trial. The company has only one approve drug in the market with revenue less than $500M in 2023. In a few years, CORT will become a well known BP, or be acquired like one.

User Image Yourmatefromdownunder Posted - 1 month ago

$CORT Adding some additional shares today, building a nice position. Good long term bet here.

User Image dinoz1001 Posted - 1 month ago

$CORT ready to fill that huge gap

User Image Nosh Posted - 1 month ago

$CORT Looking ready for a bounce here...may do an entry this week.

User Image gucag006 Posted - 1 month ago

$CORT My fellow longs, when the current round of stock buyback is consummated, the outstanding shares will be reduced to about 91 to 92 million shares. To be calibrated, all large biotechs' share outstanding are in the hundreds of millions to billions. Bottom line: not only SP is cheap, but each share is more valuable than others. Assuming there is no stock split, we will see triple digit SP soon when Relacorilant and ovarian cancer drugs are introduced to the market, but it will only be the beginning of the story as the company's pipeline is long and deep. It will take more than 5 years to go thru those clinical trials, and I think quadruple digit SP is not out of the question had it not been acquired by that time.

User Image insiderbuyingselling Posted - 1 month ago

$CORT new insider selling: 1000 shares. http://insiderbuyingselling.com/?t=CORT

User Image gucag006 Posted - 1 month ago

$CORT Sharing a conversation.

User Image insiderbuyingselling Posted - 1 month ago

$CORT new insider selling: 31828 shares. http://insiderbuyingselling.com/?t=CORT

User Image UncleStock Posted - 1 month ago

$EGRX $INVA $HRMY $CORT suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image BioTekk Posted - 1 month ago

$CORT Forget about the patent case. The real gamechanger will be relacorilant. It will take all of Korlym sales. Expect Phase III in April and NDA filing by the end of Q2. Does not make sense to start generic Korlym with a possible approval of relacorilant by Q1/2025.

User Image Psalms23 Posted - 1 month ago

$CORT Company approved a $200 mil stk buyback or approx. 10% of the outstanding shares. Only 90 mil shares will be outstanding. If the patent Appeal holds up in late Fall, the shorts are going to get squeezed. This is a better setup than the Herbalife scorching with Ackman and Icahn. The downside risk remains low with significant upside potential.

Analyst Ratings
Truist Securities Buy Feb 16, 24
HC Wainwright & Co. Buy Jan 2, 24
Canaccord Genuity Buy Dec 13, 23
Truist Securities Buy Nov 6, 23
HC Wainwright & Co. Buy Nov 2, 23
Truist Securities Hold Oct 2, 23
Canaccord Genuity Buy Aug 25, 23
Piper Sandler Overweight Aug 3, 23
Truist Securities Hold Aug 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Swisher Daniel N JR Director Director Feb 01 Sell 22 2,200 48,400 02/02/24
Swisher Daniel N JR Director Director Feb 01 Option 5.86 2,200 12,892 2,200 02/02/24
Hunt Hazel Chief Scientific Off.. Chief Scientific Officer Jan 08 Option 3.02 50,000 151,000 123,146 01/12/24
Swisher Daniel N JR Director Director Jan 02 Sell 22.11 2,200 48,642 01/04/24
Swisher Daniel N JR Director Director Jan 02 Option 5.86 2,200 12,892 2,200 01/04/24
Guyer William Chief Development Of.. Chief Development Officer Dec 22 Sell 32 10,000 320,000 6,643 12/22/23
Guyer William Chief Development Of.. Chief Development Officer Dec 22 Option 19.26 10,000 192,600 16,643 12/22/23
Robb Gary Charles Chief Business Offic.. Chief Business Officer Dec 04 Sell 26.64 7,593 202,278 21,390 12/06/23
Robb Gary Charles Chief Business Offic.. Chief Business Officer Dec 04 Option 3.29 15,000 49,350 37,771 12/06/23
Swisher Daniel N JR Director Director Dec 01 Sell 25.47 2,200 56,034 12/05/23
Swisher Daniel N JR Director Director Dec 01 Option 5.86 2,200 12,892 2,200 12/05/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Dec 01 Option 11.35 5,000 56,750 8,286 12/05/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Dec 01 Sell 26 5,000 130,000 5,854 12/05/23
Maduck Sean See Remarks See Remarks Dec 01 Sell 25.56 25,000 639,000 73,291 12/05/23
Maduck Sean See Remarks See Remarks Dec 01 Option 2.95 25,000 73,750 98,291 12/05/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Nov 01 Sell 28.1 5,000 140,500 5,854 11/03/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Nov 01 Option 11.35 5,000 56,750 9,831 11/03/23
Maduck Sean See Remarks See Remarks Nov 01 Sell 28.1 25,000 702,500 73,291 11/03/23
Maduck Sean See Remarks See Remarks Nov 01 Option 2.61 25,000 65,250 93,179 11/03/23
Swisher Daniel N JR Director Director Nov 01 Sell 27.96 2,200 61,512 11/03/23
Swisher Daniel N JR Director Director Nov 01 Option 5.86 2,200 12,892 2,200 11/03/23
Maduck Sean See Remarks See Remarks Oct 10 Sell 27.29 18,471 504,074 73,291 10/12/23
Maduck Sean See Remarks See Remarks Oct 10 Option 2.82 18,471 52,088 92,081 10/12/23
Maduck Sean See Remarks See Remarks Oct 06 Sell 27.24 3,498 95,286 73,610 10/10/23
Maduck Sean See Remarks See Remarks Oct 06 Option 3.02 3,498 10,564 77,108 10/10/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Oct 06 Sell 27.24 2,582 70,334 5,854 10/10/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Oct 06 Option 11.35 2,582 29,306 8,436 10/10/23
Maduck Sean See Remarks See Remarks Sep 18 Sell 32.48 25,000 812,000 73,610 09/20/23
Maduck Sean See Remarks See Remarks Sep 18 Option 3.02 25,000 75,500 98,610 09/20/23
Robb Gary Charles Chief Business Offic.. Chief Business Officer Sep 19 Sell 32.7354 5,000 163,677 21,996 09/20/23
Robb Gary Charles Chief Business Offic.. Chief Business Officer Sep 14 Option 3.29 13,963 45,938 34,992 09/18/23
Swisher Daniel N JR Director Director Sep 01 Sell 32.82 3,750 123,075 09/06/23
Swisher Daniel N JR Director Director Sep 01 Option 6.21 3,750 23,288 2,200 09/06/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Sep 01 Sell 32.73 5,000 163,650 5,132 09/06/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Sep 01 Option 11.35 5,000 56,750 10,132 09/06/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Aug 21 Sell 31.19 4,588 143,100 5,132 08/22/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Aug 21 Option 9.81 4,588 45,008 9,720 08/22/23
MAHONEY DAVID L Director Director Aug 14 Sell 30.95 25,000 773,750 1,222,078 08/16/23
Hunt Hazel Chief Scientific Off.. Chief Scientific Officer Aug 08 Option 3.02 50,000 151,000 123,146 08/09/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Aug 07 Sell 31.22 412 12,863 4,720 08/09/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Aug 07 Option 8.27 412 3,407 5,132 08/09/23
Swisher Daniel N JR Director Director Aug 07 Sell 30.15 2,850 85,928 08/09/23
Swisher Daniel N JR Director Director Aug 07 Option 6.21 2,850 17,698 2,850 08/09/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Jun 06 Sell 23.6 10,000 236,000 5,132 06/07/23
Lyon Joseph Douglas Chief Accounting Off.. Chief Accounting Officer Jun 06 Option 11.35 10,000 113,500 15,132 06/07/23
Robb Gary Charles Chief Business Offic.. Chief Business Officer May 09 Sell 23.97 44,000 1,054,680 19,997 05/11/23
Robb Gary Charles Chief Business Offic.. Chief Business Officer May 05 Option 2.61 105,000 274,050 124,583 05/09/23
MAHONEY DAVID L Director Director May 08 Option 1.74 30,000 52,200 1,239,275 05/09/23
Robb Gary Charles Chief Business Offic.. Chief Business Officer Sep 07 Sell 26.06 50,000 1,303,000 49,544 09/08/22
Maduck Sean See Remarks See Remarks Sep 01 Option 3.29 25,000 82,250 79,618 09/06/22